Target Audience

Psychiatrists

Learning Objective
After discussing data related to impairments in academic performance, social relationships, and driving behaviors, you will be able to evaluate the benefits of treatment for adolescents. You will also be better able to tailor an effective treatment strategy to meet the needs of your adolescent patients and improve overall functional outcomes.

Accreditation/Designation of Credit Statements
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Veritas Institute for Medical Education, Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Financial Disclosure Statements
In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Disclosures are as follows:

Jeffrey Newcorn, MD―Cephalon Inc, Cortex Pharmaceuticals Inc, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Ortho-McNeil, Pfizer Inc, Shire (grant/research support, speakers bureau, and/or consultant).

Timothy E. Wilens, MD―Abbott Laboratories, Cephalon Inc, Eli Lilly and Company, Janssen Pharmaceutica Products LP, National Institute of Mental Health, National Institute on Drug Abuse, Neurosearch, Novartis Pharmaceuticals Corporation, Ortho-McNeil, Pfizer Inc, Shire (grant/research support, speakers bureau, and/or consultant).

The staff of Veritas Institute for Medical Education, Inc. has nothing to disclose.

Unlabeled Use Disclosure Statement
Participants are advised that this CME activity will contain references to unlabeled/unapproved/ investigational uses of guanfacine, clonidine, methylphenidate, amphetamine compounds, and atomoxetine.

Method of Participation
Listen to the prerecorded telesymposium and complete the CME Activity Posttest and Evaluation and Request for Credit Form. You will receive your CME certificate immediately. This activity is provided free of charge to participating physicians.

Disclaimer
The opinions expressed in this activity are those of the presenters and not necessarily those of Veritas Institute for Medical Education, Inc. or McNeil Pediatrics division of McNeil-PPC, Inc. Please consult the appropriate package insert for full prescribing information on all drug therapies discussed.

Managing ADHD Impairments in Adolescents Transitioning to Adulthood
Jeffrey Newcorn, MD

Release Date: October 2007

Expiration Date: September 30, 2008

 Please enter a valid e-mail address in the space below to access the CME Activity Posttest and Evaluation and Request for Credit Form

Sponsored by Veritas Institute for Medical Education, Inc.

Supported by an educational grant from McNeil Pediatrics division of McNeil-PPC, Inc. administered by Ortho-McNeil Janssen Scientific Affairs, LLC.